Press release: Cell & gene therapy accelerator to de-risk early stage research

Published on June 29, 2021

Ncardia is proud to be a partner of the Cell and Gene Therapy Accelerator program, which was launched today by Brussels South Charleroi BioPark, the science-driven biopark at the heart of Europe. The program aims to de-risk early stage research and create the advanced therapy companies of the future. With access to industry expertise and scientific infrastructure plus up to €500,000 in funding per project, the Accelerator has been established to de-risk research at the proof-of-concept stage. The financing comes from BSCB’s Butterfly Fund and regional non-dilutive R&D grants from the Walloon Region. The program is co-chaired by Drs Miguel Forte (Bone Therapeutics, ARM1 and ISCT²) and Christian Homsy (Capstan Therapeutics, ex Celyad).

Continue reading on website
Other news

Abzena appoints Patrice Dudley Aviles as Chief Human Resource Officer

June 28, 2021
Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Patrice Dudley Aviles as the Chief Human Resource Officer.With over 25 years’ experience in the Pharmaceutical industry, Patrice has previously held roles with progressively increasing scope and responsibility at Pfizer,

BioPharm Intl: Defining a Holistic Approach to mAb Purification Processes

July 1, 2021
Understanding the process and product goals is just the first step to a holistic approach to process development.Advances in upstream processing of monoclonal antibodies (mAbs) have resulted in increasing titers, cell densities, and other properties that have challenged existing downstream processing operations. It is essential when developing downstream mAb purification processes to understand th